Dr. Pierre Falardeau

Pierre has been in the biotech industry for more than 20 years leading private and public companies from early preclinical stage to phase 3. His focus is in building best value to shareholders by identifying opportunities and building effective teams around it who deliver on target. Over the last 15 years, Pierre has raised more than $150M in capital and lead M&A and partnership transactions.

Pierre Falardeau is President and Chief Executive Officer of Verlyx Pharma (previously Oncozyme pharma) since January 2010 and chairman of the Board of Folia Biotech. Pierre is also greatly involved in the biotech sector in Canada being an executive member of the board of BioQuebec and Montreal in Vivo.

Prior to that, he was an Associate Professor at the Faculty of Pharmacy, Laval University, leading a Neuroscience Research Group at the Centre de Recherche du CHUL in Quebec. He graduated from Laval University with a Ph.D. in Pharmacology followed by a 5-year post-doctoral fellow at the Howard Hugues Medical Institute at Duke University in North Carolina with Drs Marc Caron et Robert Lefkowitz (Nobel prize of Medicine, 2012).

Pierre is based in Montreal, Canada.